Biogen and Isis teamed up for the fourth time in a new deal worth $450 million, focused on CNS disorders; Stryker gained robotic-assisted surgery expertise in its $1.4 billion acquisition of MAKO Surgical. Biopharma financing more than doubled in September compared with the previous month, reaching $1.7 billion and boosted by KV Pharma’s $375 million offering; device fundraising also increased, to $205 million, driven by early-stage venture rounds.
Exhibit 1
Top Alliances In September 2013
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
